Clinical application and efficacy analysis of mirikizumab

Milikizumab (Mirikizumab) is a monoclonal antibody with IL-23p19 as a specific target. It has gradually become a new immune regulation regimen recommended by international guidelines in the treatment of ulcerative colitis (UC) and Crohn's disease (CD). The logic of its clinical application (UC and CD) mainly stems from the central role of IL-23 in inflammatory bowel disease: this cytokine continuously stimulates submucosal immune cells, allowing intestinal inflammation to be repeatedly amplified. By blocking IL-23, militizumab can effectively reduce intestinal inflammatory response and gradually restore the damaged intestinal mucosal environment.

In ulcerative colitis, militizumab can reduce symptoms related to inflammation of the mucosal surface, such as rectal bleeding, abdominal pain, and urgency to defecate. Its medicinal effect is of a gradual accumulation type. With continued treatment, the ulcerated surface of the colon mucosa can gradually shrink, improving the appearance of the mucosa under endoscopic examination. Many patients experience significant reductions in symptom fluctuations during maintenance treatment, which is of great significance for patients with recurrent UC.

In Crohn's disease, the efficacy of militizumab is more reflected in the stability of deep inflammation. For example, some patients' long-term diarrhea, abdominal discomfort, and weight loss showed a significant improvement trend after treatment. At the same time, since Crohn's disease may involve multiple areas such as the stomach, small intestine, colon, etc., the systemic immune regulation mechanism of milizumab is suitable for this kind of "segmentally and widely" distributed lesions.

Another advantage of the drug's efficacy is that it does not rely on strong systemic immunosuppression, but more precisely inhibits IL-23 signaling, so its tolerability is ideal. Many patients can use it long-term without frequent drug changes, which expands the scope of clinical applications of militizumab, including treatment-naïve patients, those refractory to other biologics, and patients with chronic active IBD who require long-term maintenance therapy.

Reference materials:https://omvoh.lilly.com/